ADAM10在阿尔茨海默病发病机制中的作用  

The role of ADAM10 in the pathogenesis of Alzheimer disease

作　　者：王雨欣 王蓉[1] Wang Yuxin;Wang Rong(Department of Central Laboratory,Xuanwu Hospital,Capital Medical University,Beijing 100053,China)

机构地区：[1]首都医科大学宣武医院中心实验室,北京100053

出　　处：《神经疾病与精神卫生》2024年第1期42-47,共6页Journal of Neuroscience and Mental Health

基　　金：国家重点研发计划(2022YFC2403500)。

摘　　要：阿尔茨海默病(AD)是一种进行性加重的神经系统退行性疾病,特征是学习记忆功能下降、多个认知领域受损,最终无法执行日常任务。越来越多的证据表明,靶向Aβ仍是目前AD诊断和治疗的重要策略。去整合素金属蛋白酶10(ADAM10)作为淀粉样蛋白前体蛋白切割过程中的关键分泌酶,不仅能减少Aβ的产生,还影响AD的病理,包括减少tau蛋白过度磷酸化、维持正常的突触功能、促进海马神经发生和神经元网络的稳态。ADAM10可能成为早期和准确诊断AD的生物标志物。本文对ADAM10性质及其在AD发病机制中的作用进行综述,并讨论ADAM10作为治疗AD靶点的潜力,以期为AD的深入研究和治疗提供理论基础和思路。Alzheimer disease(AD)is a progressive neurodegenerative disease characterized by a decline in learning and memory,impairment of multiple cognitive domains,and ultimately inability to perform daily tasks.More and more evidence suggests that targeting Aβproduction to reduce its deposition is a therapeutic option for AD pathology.As a key secretory enzyme in the process of amyloid precursor protein cleavage,ADAM10 can not only reduce the production of Aβ,but also affect the pathology of AD,including reducing tau protein hyperphosphorylation,maintaining normal synaptic function,and promoting hippocampal neurogenesis and neuronal network homeostasis.ADAM10 may be a biomarker for early and accurate diagnosis of AD.This article will review the nature of ADAM10 and its role in the pathogenesis of AD,and discuss the potential of ADAM10 as a target for the treatment of AD,in order to provide a theoretical basis and new ideas for the indepth study and treatment of AD.

关 键 词：阿尔茨海默病 去整合素金属蛋白酶10 淀粉样前体蛋白 Β-淀粉样肽 综述 

分 类 号：R749.16[医药卫生—神经病学与精神病学]